The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Seven days of antibiotics was noninferior to 14 days for treating Gram-negative bloodstream infections, supporting shorter ...

Antimicrobial resistance not only undermines the efficacy of current treatments but also endangers the entirety of modern ...

When people take antibiotics, some of the dose is excreted with urine and feces and ends up in our wastewater. The presence ...

In a routine blood test that turned extraordinary, French scientists have identified the world's newest and rarest blood ...

Flightpath Biosciences, Inc., a clinical stage biotechnology company focused on the development of precision therapeutics targeting bacterial ...

A new study projects that millions of stomach cancer cases globally could be fueled by the Helicobacter pylori bacteria.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya (pivmecillinam ...

DURHAM, NC, USA and BEIJING, China I July 3, 2025 I Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing ...

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...

Researchers from the National University of Singapore (NUS) have solved a 60-year-old mystery in bacterial cell envelope ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that the United States Patent and Trademark ...